"Does Medicare cover Zepbound" has two correct answers in 2026, and which one applies to you depends entirely on why the drug is prescribed. Medicare has never been allowed to pay for drugs used purely for weight loss — but Zepbound carries a second FDA indication that slips through that exclusion, and since July 1, 2026, a federal demonstration program has bypassed the exclusion altogether.
Direct answer: Yes — through two different doors. Door 1 (open now): Medicare Part D plans can cover Zepbound when it's prescribed for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, an FDA indication Zepbound has held since December 2024. Coverage depends on your plan's formulary and almost always requires prior authorization with a sleep study. Door 2 (open since July 1, 2026): the Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight loss at a flat $50/month through December 31, 2027, for beneficiaries who meet BMI-based criteria. What Medicare still won't do in 2026 is cover Zepbound for weight loss through your regular Part D benefit — and the single-dose vials and pens aren't in the Bridge at all.
Lilly itself now advertises both doors: zepbound.lilly.com lists "Zepbound coverage through the Medicare GLP-1 Bridge for no more than $50/month" for eligible Medicare Part D patients whose prescription is for weight management, subject to the Bridge's clinical criteria.
Zepbound Medicare Coverage: Every Path in One Table
| Your situation | Does Medicare cover it? | What you pay |
|---|---|---|
| Moderate-to-severe OSA + obesity | Yes — Part D, if on formulary (prior auth) | Plan cost-sharing; roughly $160-190/month average until you hit the $2,100 cap |
| Weight loss only, meet Bridge criteria | Yes — GLP-1 Bridge, live since July 1, 2026 | $50/month flat (KwikPen only) |
| Weight loss only, before July 1, 2026 (historical) | No | Cash: $299-$449/month via LillyDirect |
| Weight loss only, don't meet Bridge criteria | No | Cash routes (below) |
| Type 2 diabetes | Not Zepbound — but Part D covers Mounjaro (same drug, tirzepatide, diabetes label) | Plan cost-sharing |
Zepbound Medicare Coverage for Sleep Apnea: The Part D Path
In December 2024, the FDA approved Zepbound to treat moderate-to-severe OSA in adults with obesity. That matters because Medicare's weight-loss exclusion only blocks drugs when used for weight loss — a GLP-1 prescribed for a different medically accepted indication is fair game for Part D. CMS confirmed this, listing OSA alongside type 2 diabetes and MASH as Part D-coverable GLP-1 indications.
The catch is execution:
- Formularies vary. Plans can cover Zepbound for OSA; not all do. Check your plan's formulary in Medicare's plan finder before assuming anything.
- Prior authorization is nearly universal. Expect to submit a sleep study (lab or home-based) confirming moderate-to-severe OSA, BMI documentation, and a statement that the prescription is for OSA — not weight.
- If it's not on formulary, you can request an exception. CMS explicitly requires Part D sponsors to run their normal formulary-exception process for OSA prescriptions rather than shunting people to the Bridge.
- Costs count toward the cap. Unlike the Bridge, Part D spending on Zepbound counts toward 2026's $2,100 out-of-pocket maximum, after which you pay $0 for the rest of the year.
Important: if you qualify for the OSA pathway, you cannot use the Bridge — CMS rules send anyone with a Part D-coverable indication through their Part D plan, even if their BMI also meets Bridge criteria.
Zepbound Medicare Coverage for Weight Loss: The $50 Bridge (Live Since July 1, 2026)
The Medicare GLP-1 Bridge program is a CMS demonstration running July 1, 2026 through December 31, 2027 that covers weight-loss GLP-1s outside the normal Part D benefit. For Zepbound specifically:
- Only the KwikPen formulation is included. Single-dose vials and single-dose pens are excluded — if you've been buying $299-$449 LillyDirect vials, the $50 price requires switching to the multi-dose KwikPen.
- The copay is a flat $50 per monthly supply, every month, with manufacturers supplying the drug at a negotiated $245 net price.
- Eligibility is BMI-tiered, measured when you started therapy: BMI ≥35 alone; BMI ≥30 plus heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 plus pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
- Plan type matters: you need a standalone PDP or an HMO/HMO-POS/local-or-regional-PPO Medicare Advantage drug plan (MA-PD). Special needs plans, employer/union group waiver plans and the LI NET program are eligible too; private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans and religious fraternal benefit plans are not, unless you also hold a standalone PDP. Dually eligible beneficiaries in an eligible plan type do qualify.
- No sign-up, but the order of operations matters. Your prescriber sends the KwikPen prescription to a pharmacy first. The pharmacy bills CMS's central processor, and the prior authorization request comes back to the prescriber from there — filing it before a pharmacy claim exists returns a "patient not found" error. The prescriber then attests, under penalty of perjury, that you met the BMI criteria when you started GLP-1 therapy and are doing structured nutrition and physical activity alongside the drug.
- The $50 doesn't count toward your deductible, TrOOP, or the $2,100 cap, and Extra Help/LIS subsidies don't reduce it.
Wegovy (all forms) and Foundayo, Lilly's new GLP-1 pill, are the other two Bridge drugs — the full program rules, timeline, and exclusions are in our dedicated Bridge guide.
Which Zepbound Pen Types Medicare Covers
Zepbound ships in four different devices, and Medicare does not treat them alike. The Bridge list is device-specific: CMS names the single-patient-use KwikPen and nothing else, down to the NDC.
| Zepbound formulation | Doses per device | On the $50 Bridge? | Part D (OSA indication) |
|---|---|---|---|
| Single-patient-use KwikPen, 2.5-15 mg | 4 weekly doses per pen | Yes — the only Zepbound device CMS lists | If your plan's formulary includes it |
| Prefilled single-dose pen (4-pack) | 1 dose per pen | No — named as excluded | If your plan's formulary includes it |
| Single-dose vial (1- or 4-pack) | 1 dose per vial | No — named as excluded | If your plan's formulary includes it |
| Multi-dose vial | 4 weekly doses per vial | No — not on the CMS NDC list | If your plan's formulary includes it |
The six Zepbound NDCs CMS published for the Bridge — 0002-3511-11, 0002-3522-11, 0002-3533-11, 0002-3544-11, 0002-3555-11 and 0002-3566-11 — are the 15 mg, 12.5 mg, 10 mg, 7.5 mg, 5 mg and 2.5 mg KwikPens, in that order. Any other Zepbound NDC billed to the Bridge will not pay. CMS has said the product and NDC list may be updated during the demonstration, so a formulation excluded today is not necessarily excluded in 2027.
Two consequences people find out at the counter:
- Pen needles are not covered. CMS states that pen needles for the KwikPen are not covered by the Bridge and should not be billed to the Bridge or to your Part D plan. You buy them separately.
- The KwikPen runs on its own clock. Each pen holds four weekly doses. Unopened and refrigerated, it is good until the date on the label; at room temperature, discard an unopened pen after 30 days. Once in use, discard it after 30 days at room temperature, 30 days after first use, or after four weekly doses — whichever comes first, even if solution is left. Single-dose pens and vials follow a different rule: refrigerate, with up to 21 total days at room temperature.
Getting Medicare Approval for Zepbound: Bridge Versus Non-Bridge
There are two separate approvals, running on separate rails, and the non-Bridge one is the only one you can appeal.
| Approval mechanics | Medicare GLP-1 Bridge (weight loss) | Non-Bridge: Part D (OSA and other covered indications) |
|---|---|---|
| Who decides | A single CMS central processor, outside your Part D plan | Your Part D plan |
| What starts it | Prescriber sends the KwikPen prescription to a pharmacy; the pharmacy bills the Bridge, and the prior authorization request goes from there to the prescriber | Prescriber requests a coverage determination and files the plan's prior authorization |
| Part D denial needed first? | No | Not applicable |
| Timing | Prior authorization request reaches the prescriber typically within 24-72 hours; the decision is sent to the prescriber and mailed to you within 72 hours of submission | Standard Part D coverage-determination timelines |
| What is attested | Under penalty of perjury: age 18+, BMI tier met at the time therapy started, prescribed to reduce and maintain weight alongside structured nutrition and physical activity | Medical necessity for the FDA-approved indication, usually with a sleep study for OSA |
| How long it lasts | Through December 31, 2027, carrying across refills and dose changes, unless you switch to a different GLP-1 | Plan-defined, commonly re-authorized each year |
| If denied | No appeals process. The prescriber can only resubmit the form with corrected or additional information | Full appeal ladder: redetermination, then an independent review entity, and beyond |
| Cost to you | $50 flat, outside the deductible, TrOOP and the $2,100 cap; no Extra Help reduction | Plan cost-sharing, which counts toward the $2,100 cap |
Three details worth planning around. The prescriber cannot get ahead of the pharmacy — a prior authorization filed before a pharmacy claim exists comes back "patient not found," so the order is prescription, pharmacy claim, prior authorization. CMS may verify what was attested against its own Medicare data, including whether you have type 2 diabetes. And because the Bridge has no appeal, a resubmission with better documentation is the only remedy; the prescriber call center for Bridge prior authorizations is 855-273-0102, weekdays 8am-7pm ET.
One overlap that catches people at the BMI ≥27 tier: CMS does not make prescribers attest that you have no cardiovascular disease, but it does make them attest that the drug is prescribed to reduce and maintain weight. If a GLP-1 is being prescribed to reduce the risk of major adverse cardiovascular events — even if it is also prescribed for weight — CMS says that prescription belongs with your Part D plan rather than the Bridge.
What Zepbound Costs on Medicare in 2026
| Route | Formulation | Monthly cost | Available |
|---|---|---|---|
| Part D (OSA indication) | Any covered form | Plan-dependent, ~$160-190 average; $0 after $2,100 cap | Now |
| GLP-1 Bridge (weight loss) | KwikPen only | $50 flat, pen needles not included | Now, through Dec 31, 2027 |
| LillyDirect self-pay (cash, no insurance involved) | KwikPen/vials | $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg+) | Now |
| Lilly savings card | Single-dose pens | $25 with commercial insurance — government beneficiaries excluded | Not for Medicare |
That last row trips people up constantly: Lilly's $25 savings card legally excludes anyone on Medicare, Medicaid, or TRICARE. A Medicare beneficiary's discount options are the Bridge, the OSA pathway, or paying cash entirely outside insurance — covered in detail in our Zepbound coupon guide. Medicare.gov also points beneficiaries to TrumpRx.gov to compare cash prices on GLP-1s, with the caveat that discount cards are not creditable coverage: what you spend through them does not count toward your Part D deductible or your out-of-pocket maximum. Whether a cheaper generic version exists is a separate question, answered in our Zepbound generic guide.
Which Zepbound Coverage Path Fits Your Situation
- You have diagnosed moderate-to-severe OSA and obesity: pursue Part D now. Ask your doctor to file prior authorization with your sleep study attached; request a formulary exception if Zepbound isn't listed.
- You want Zepbound for weight loss and meet a BMI tier: the Bridge is open. Have your prescriber send a KwikPen prescription to your pharmacy; the prior authorization request comes back to them within roughly 24-72 hours. Budget $50/month plus pen needles, which the Bridge does not cover.
- You suspect sleep apnea but were never tested: a sleep study could open the Part D door today — and OSA is badly underdiagnosed in the Bridge's exact demographic.
- You have type 2 diabetes: you're in the wrong aisle — Part D covers Mounjaro, the diabetes-labeled tirzepatide, instead.
- None of the above: cash routes below.
If Your Part D Plan Denies Zepbound
Denials for OSA prescriptions are appealable. The sequence: ask the plan for a coverage determination with your prescriber's supporting statement → if denied, file a redetermination (first appeal) within 65 days → escalate to an independent review entity. Most successful Zepbound appeals hinge on documenting the OSA diagnosis clearly and showing the prescription is for the FDA-approved OSA indication, not weight loss. Our GLP-1 insurance coverage guide walks through appeal templates, and cheapest GLP-1 ranks the fallback options by price.
If You Can't Get Zepbound Covered at All
On Medicare but locked out until July — or not eligible at all? Pallas Health — a 100% online visit reviewed by a US-licensed clinician, who prescribes only when it is clinically appropriate. FDA-approved options, or compounded medication prepared by US-licensed pharmacies. Ships free if you are eligible, with no membership or platform fees. (Partner link: we may earn a commission. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs.)
Frequently Asked Questions
Does Medicare cover Zepbound for weight loss in 2026? Not through regular Part D — the weight-loss exclusion still applies. But since July 1, 2026, and through December 31, 2027, the Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight loss at a flat $50/month for beneficiaries who meet BMI-based criteria.
Does Medicare cover Zepbound for sleep apnea? Yes, it can. Zepbound has been FDA-approved for moderate-to-severe OSA in adults with obesity since December 2024, which makes it Part D-coverable. Coverage depends on your plan's formulary and requires prior authorization with a sleep study.
How much is Zepbound with Medicare? On the OSA pathway, plan cost-sharing applies — roughly $160-190/month on average until you reach the $2,100 annual out-of-pocket cap. On the Bridge (from July 2026), it's a flat $50/month for the KwikPen.
Can Medicare patients use the Zepbound savings card? No. Lilly's $25 savings card excludes all government beneficiaries, including Medicare. Medicare patients can still pay cash through LillyDirect ($299-$449/month) since that bypasses insurance entirely.
Are Zepbound vials covered by the Medicare Bridge program? No. Only the KwikPen formulation is included in the Bridge. Single-dose vials and single-dose pens are explicitly excluded.
Which is better for me — the OSA pathway or the Bridge? You don't get to choose: CMS rules say anyone with a Part D-coverable indication (like OSA) must use Part D. The Bridge is only for people whose sole indication is weight management.
Which Zepbound pen types are approved by Medicare? For the $50 Bridge, only the single-patient-use KwikPen. CMS lists six KwikPen NDCs and states that the single-dose vial and single-dose pen formulations are not available through the Bridge; the multi-dose vial is not on the list either. Under regular Part D — the sleep apnea route — there is no CMS device list, so which pens or vials are covered comes down to your plan's formulary.
How do I get Medicare approval for Zepbound without going through the Bridge? Non-Bridge means Part D, and Part D needs a medically accepted indication that is not weight loss. For Zepbound that is moderate-to-severe obstructive sleep apnea with obesity. Your prescriber asks the plan for a coverage determination with a supporting statement, normally attaching the sleep study, and requests a formulary exception if Zepbound is not listed. The trade-off: this path is slower and formulary-dependent, but unlike the Bridge it has a real appeals ladder if the plan says no.
Does the Medicare Bridge cover pen needles for the KwikPen? No. CMS says pen needles are not covered by the Bridge and should not be billed to the Bridge or to your Part D plan. Budget for them separately alongside the $50 copay.
How long does a Medicare GLP-1 Bridge approval last? Through December 31, 2027, and it carries across refills and dose changes — Medicare.gov states the prior authorization stays valid unless you switch to a different GLP-1 drug. Switching starts the process over.
Last reviewed: August 20, 2026
Sources
- Medicare GLP-1 Bridge: program overview and FAQs — CMS
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries — CMS Newsroom
- Zepbound Coverage and Savings — zepbound.lilly.com
- Does Medicare Cover Zepbound for Sleep Apnea? — SleepApnea.org
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — KFF
- White House Strikes GLP-1 Pricing Deal With Lilly, Novo — BioSpace
- What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries — KFF
- Medicare GLP-1 Bridge: Information for Providers — CMS
- Medicare GLP-1 Bridge: Information for Pharmacies (eligible drugs, formulations and NDCs) — CMS
- Weight loss drugs: Medicare GLP-1 Bridge — Medicare.gov
- Costs for Medicare drug coverage (2026 out-of-pocket cap) — Medicare.gov
- ZEPBOUND (tirzepatide) prescribing information: dosage forms, NDCs and storage — DailyMed
